Study S002178

The Effect of Oral Semaglutide 50 mg Once-daily on Energy Intake, Gastric Emptying, Appetite, Control of Eating and Pharmacokinetics in Participants With Obesity

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT05236517
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 60
Start: 2022-02-08
Primary completion: 2022-09-29
Lead sponsor: Novo Nordisk A/S
Conditions: Obesity
Interventions: DRUG:Semaglutide D Dose 1; DRUG:Semaglutide D Dose 2; DRUG:Semaglutide D Dose 3; DRUG:Semaglutide C Dose 4; DRUG:Semaglutide C Dose 5 (50 mg); DRUG:Placebo (Semaglutide C); DRUG:Placebo ( Semaglutide D)
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: EUDRACT_NUMBER:2021-003341-38; OTHER:U1111-1266-4375

Registered primary outcomes

Relative change in energy intake during ad libitum lunch [Baseline to Day 140]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0018819	Effect of oral semaglutide on energy intake, appetite, control of eating and gastric emptying in adults living with obesity: A randomized controlled trial. Gabe MBN, Diabetes, obesity & metabolism	2024	Randomized trial	PMID 39082206 DOI	registry reference RESULT:39082206